Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology.
TL;DR: The molecular interaction map (MIM) notation is described formally and its merits relative to alternative proposals are discussed and it is shown by simple examples how to denote all of the molecular interactions commonly found in bioregulatory networks.
Journal ArticleDOI
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Yves Pommier,Mark Cushman +1 more
TL;DR: The use of γ-H2AX as a pharmacodynamic biomarker for the clinical development of the indenoisoquinolines is discussed, which results in the rapid and sustained phosphorylation of histone H2AX.
Journal Article
Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
François Goldwasser,Tsunehiro Shimizu,Joany Jackman,Yuko Hoki,Patrick M. O'Connor,Kurt W. Kohn,Yves Pommier +6 more
TL;DR: Analysis of the 7 human colon carcinoma cell lines of the NCI Anticancer Drug Screen showed that defects in replicon elongation and G2 breakthrough capability correlate with sensitivity to CPT, and that CPT appears to have two cytotoxic mechanisms, one protectable by aphidicolin, and the other not.
Journal Article
Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
TL;DR: Heterogeneity of cell death mechanisms after exposure to topoisomerase II inhibitors among human cancer cell lines is indicated, especially in HT-29 and HL-60.
Journal ArticleDOI
Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†
Jessica Marinello,Christophe Marchand,Bryan T. Mott,Anjali Bain,Craig J. Thomas,Yves Pommier +5 more
TL;DR: It is demonstrated that both raltegravir and elvitegravIR are potent IN inhibitors and are highly selective for the ST reaction of IN.